P
P

Pfizer

交易方向

交易者脈動

技術摘要

小時

財經新聞

New York Times business news - Jan. 18

Jan 18 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - BlackRock Inc BLK.N Chief Executive Officer Larry Fink delivered his words in annual letters on Tuesday that have drawn remarkable attention, but also criticism from all corners:
A
P
V
A
U

Pfizer to boost 19 pill production with French deal

PARIS, Jan 17 (Reuters) - Pfizer PFE.N will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million) in the country over the next five years, the U.S. drugmaker said on Monday. The decision is part of Pfizer's strategy to boost global production of the pill, paxlovid, which was
P

Financial Times - Jan 17

Jan 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Horta-Osório resigns as Credit Suisse chair over COVID-19 breaches Link GSK and Pfizer hold out for 60 bln pounds bid for consumer health unit Link BBC licence fee to be abolished in 2
C
G
P

Pfizer says it applied for Japan gov't approval for oral 19 drug

TOKYO, Jan 14 (Reuters) - U.S. drugmaker Pfizer Inc PFE.N said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment. The application is based on global Phase II/III trials that Japan was part of, Pfizer said in a statement. With COVID-19 cases surging again, Japan is betting heavily on oral treatments to keep se
P

Pfizer says it applied for Japanese govt approval for oral 19 drug

TOKYO, Jan 14 (Reuters) - Pfizer Inc PFE.N said on Friday it applied for Japanese government approval for its oral COVID-19 treatment. Japanese Prime Minister Fumio Kishida said last month he spoke with Pfizer CEO Albert Bourla to secure 2 million doses of Pfizer's antiviral pill. Reporting by Rocky Swift; Editing by Jacqueline Wong
P

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明